Indian diabetic population on Human Mixtard concerned on changes in insulin therapy: Nandita Vijayasimha, Bengaluru Thursday, April 24, 2025, 08:00 Hrs [IST] India’s diabetic po ...

After selling off a portion of its diabetes care business last year, Ypsomed is now fully exiting the diabetes care business ...

Novo Nordisk clarifies Human Mixtard penfill to be replaced with injectables: Our Bureau, Bengaluru Wednesday, April 23, 2025, 13:30 Hrs [IST] Denmark-based global pharma major, N ...

Thirty-seven-year-old Nupur Lalvani, who has been living with Type 1 diabetes since the age of eight, was dependent on ...

In a move which could shake up the diabetes market, Novo Nordisk is discontinuing the country’s largest selling insulin, ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Report Ocean, a leading strategic consulting and market research firm, in its recent study, estimated the Asia Pacific Lancet and Pen Needles Market size at USD 1,416.30 million in 2023. During the ...

Novo Nordisk’s insulin brand Mixtard will continue to be available in vials, the Danish healthcare company clarified, even as ...

Danish pharmaceutical giant Novo Nordisk has announced plans to phase out Human Mixtard, India's top-selling insulin brand.

Novo Nordisk has said it is discontinuing selling its popular, best-selling insulin brand in India and will instead promote ...

Novo Nordisk will discontinue Human Mixtard, a top-selling insulin in India. This decision aligns with the company's global ...

T he US Food and Drug Administration (FDA) and pharmaceutical company Novo Nordisk are now in an attempt to making more ...